Research Articles
Evidence-based research on metabolic health, GLP-1 therapeutics, and peptide science.
Childhood Obesity in Australia: Why Individual Responsibility Framing Has Failed and What Policy Must Change
One in four Australian children is overweight or obese. A policy analysis of why 'eat less, move more' campaigns fail, and what evidence-based interventions — sugar taxes, advertising bans, food labelling reform, and school food environments — can actually work.
Rural and Remote Health Access in Australia: The Policy Gap That's Costing Lives
Rural Australians die on average two years younger than their city counterparts. A policy analysis of the GP workforce crisis, specialist access deserts, the MBS telehealth permanency debate, RFDS funding constraints, and the concrete reforms needed to close the gap.
Pharmaceutical Price Disclosure in Australia: How the PBS Cost Reduction Mechanism Works
Australia's price disclosure regime requires pharmaceutical manufacturers to disclose actual transaction prices, triggering mandatory PBS price reductions. A policy analysis of how the mechanism works, its impact on medicine affordability, and reform priorities.
TGA Reform Priorities for 2027: Accelerating Access to Medicines for Australians
Australia's Therapeutic Goods Administration faces mounting pressure to modernise its approval pathways, expand biosimilar uptake, close the digital therapeutics regulatory gap, and strengthen post-market surveillance. A policy analysis of the reform agenda for 2027.
GLP-1 Receptor Agonists: From Type 2 Diabetes to Metabolic Health
Tracing the research history of GLP-1 receptor agonists from their origins in diabetes treatment to their growing role in obesity and metabolic health management.
Triple Receptor Agonism: The Science Behind Retatrutide Research
An in-depth look at retatrutide's GLP-1, GIP, and glucagon receptor co-agonism, the landmark phase 2 trial data, and what triple receptor activation means for metabolic science.
Australia's Public Dental Health Crisis: The Medicare Gap That Harms Millions
Dental health is excluded from Medicare despite overwhelming evidence that oral health is integral to systemic health. Here's the policy case for universal dental coverage, the cost of inaction, and what reform would look like.
Telehealth Permanency in Australia: The Case for Making COVID-Era Reforms Last
Australia's COVID-era telehealth expansion delivered measurable access gains for rural patients, mental health consumers, and specialist-deprived communities. A policy analysis of what has been made permanent, what remains under review, and why the evidence strongly supports a fully permanent tiered telehealth model.
Australia's Bulk Billing Crisis: Why Medicare Is Failing and What Needs to Change
Bulk billing rates for GP visits fell from roughly 88% in 2022 to 76% in 2024. A policy analysis of rebate indexation failures, the GP workforce crisis, out-of-pocket cost inequity, and the specific reforms needed to restore universal access to primary care.
Visceral Fat vs Subcutaneous Fat: Why Location Matters in Research
Not all body fat is equal. This article examines the distinct metabolic activity of visceral and subcutaneous adipose tissue, and why fat distribution — not just total weight — drives disease risk.
The Future of Weight Management: From Lifestyle to Pharmacotherapy
An evidence-based overview of the evolution of obesity treatment — from lifestyle intervention through bariatric surgery to next-generation pharmacotherapy — and what research suggests about long-term metabolic health management.
Mental Health Parity in Australia: The Policy Gap and Reform Priorities
Mental health conditions affect one in five Australians annually, yet mental health funding, Medicare rebates, and private health insurance coverage remain structurally inequitable compared to physical health. This analysis examines the parity gap and the policy changes needed to close it.
TGA Regulation of Peptides in Australia: What Patients and Clinicians Need to Know
Australia's Therapeutic Goods Administration classifies peptides under a complex scheduling framework. This guide explains TGA peptide schedules, the March 2025 BPC-157 rescheduling, compounding pharmacy access, and what 'research use' means legally.
Bariatric Surgery Access in Australia: Policy Failures, Equity Gaps, and the Case for Reform
Australia's bariatric surgery system is two-tiered, inequitable, and failing hundreds of thousands of people with severe obesity. A policy analysis of access barriers, public waitlist failures, the economic case for expanded funding, and the role of GLP-1 medications in reshaping the surgical pipeline.
Mental Health Medicare Reform in Australia: What's Working, What's Failing, and What Must Change
Australia's Better Access scheme has improved mental health care for many, but the 2023 reversal of 20 subsidised sessions, persistent cost barriers, workforce shortages, and system gaps leave too many people undertreated. A policy analysis of what reform is needed and why.
BPC-157 Schedule 4 in Australia: What the TGA Rescheduling Means and What Comes Next
A detailed policy and science analysis of Australia's TGA decision to reschedule BPC-157 to Schedule 4 in March 2025 — regulatory rationale, clinical implications, and the research evidence for this peptide.
The Obesity Crisis in Australia: What the Evidence Tells Us
Australia faces a serious obesity crisis. This article examines the latest prevalence data, economic burden, and why emerging metabolic science is reshaping the research landscape.
GLP-1 Medication Shortage in Australia: Policy Failures, Access Inequity, and the Path to Reform
Australia's GLP-1 receptor agonist shortage exposes deep structural failures in medicines policy. This analysis examines the supply crisis, access inequities, the compounding pharmacy debate, and six concrete reforms needed to ensure equitable access to life-changing obesity and diabetes treatments.
Peptide Storage and Stability: What Research Protocols Require
A research-focused guide to peptide stability, lyophilisation, reconstitution, and cold chain management — essential knowledge for maintaining research integrity with peptide compounds.
Australia's GP Workforce Crisis: Causes, Consequences, and Policy Solutions
Australia faces a significant and worsening GP shortage, with rural and outer-suburban communities hardest hit. This analysis examines the structural causes, the downstream effects on preventive care and hospital pressure, and the evidence-based policy reforms needed to rebuild the primary care workforce.
Preventive Health Funding in Australia: The Policy Case for Investment
Australia spends roughly 1.8% of total health expenditure on prevention versus the WHO 5% benchmark. A policy analysis of underinvestment, return on investment evidence, and costed reform proposals for 2026 and beyond.
Medicare and PBS Reform for Obesity Treatment: What Australia Needs to Do
Australia's PBS coverage of obesity medications is inadequate, inequitable, and out of step with the clinical evidence. A policy analysis of the case for expanded PBS listing of GLP-1 receptor agonists and what reform should look like.
Metabolic Syndrome in Australia: The Policy Gap Between Evidence and Action
Australia's metabolic syndrome burden is large, growing, and poorly addressed by current Medicare and public health policy. An evidence-based analysis of the gap between what the research shows and what the health system delivers.
Australia's Indigenous Health Gap: Evidence, Accountability, and Policy Action
Aboriginal and Torres Strait Islander Australians face a life expectancy gap of 8-9 years compared to non-Indigenous Australians. A policy analysis of the Closing the Gap targets, what the evidence shows works, and where structural reform must focus.
Tirzepatide Research: The Dual GIP/GLP-1 Agonist Explained
A research-focused overview of tirzepatide's dual GIP and GLP-1 receptor mechanism, SURMOUNT trial data, and why dual agonism produces superior outcomes to single-receptor therapies.
Pharmacy Scope of Practice in Australia: The Policy Case for Expansion
Australian pharmacists are among the most accessible healthcare professionals, yet their clinical scope remains narrower than international peers. A policy analysis of pharmacist prescribing, autonomous practice models, and the evidence for expanded scope in primary care.
Metabolic Syndrome: Understanding the Cluster of Conditions
A research-focused overview of metabolic syndrome — its diagnostic criteria, prevalence in Australia, and emerging evidence on peptide-based interventions targeting multiple components simultaneously.
The Women's Health Funding Gap in Australia: Policy Analysis and Reform Priorities
Women's health conditions are consistently underfunded, underresearched, and underdiagnosed in Australia. This analysis examines the endometriosis diagnostic delay, autoimmune disease burden, menopause treatment gaps, and the structural reforms needed to close the gap.
NDIS Reform 2026: Independent Review Recommendations and Implementation Progress
The 2023 NDIS Independent Review delivered 26 recommendations to fix a scheme at risk of financial collapse. Here's a policy analysis of the reform agenda, what's been implemented, and the unresolved tensions between sustainability and participant rights.
Social Determinants of Health: Australia's Structural Barriers to Equitable Outcomes
Housing instability, low income, educational disadvantage, and unemployment drive health outcomes more than healthcare access. Here's the evidence on social determinants and the policy reforms needed to address health inequality in Australia.
Aged Care Reform in Australia: Royal Commission Recommendations and Policy Gaps
The 2021 Royal Commission into Aged Care Quality and Safety delivered 148 recommendations. Here's an analysis of implementation progress, the most urgent remaining gaps, and what meaningful reform must include.
Chronic Disease Prevention Funding in Australia: The Return on Investment Case
Australia spends less than 2% of its health budget on prevention despite chronic disease representing over 70% of the disease burden. This analysis examines the economic evidence for prevention investment, what the OECD comparison shows, and the policy reforms that would shift Australia's health system upstream.